title: Cervical Cancer: Contemporary Management
author: Shalini, M.D. Rajaram
description: Shalini Rajaram MD MAMS Director Professor, Department of Obstetrics and Gynaecology, University College of Medical Sciences and Guru Teg Bahadur Hospital, Delhi, India K Chitrathara MD (OBGYN) MCh (Urology) Head of Department and Senior Consultant, Department of Surgical and Gynecologic Oncology, Lakeshore and Welcare Hospitals, Kochi, India Amita Maheshwari MD Associate Professor, Department of Gynaecologic Oncology, Tata Memorial Hospital, E Borges Marg, Parel, Mumbai, India
zlib_text:  
  International Journal of 
  Molecular Sciences
  Review
  Immunotherapy for Uterine Cervical Cancer Using
  Checkpoint Inhibitors: Future Directions
  Masahiro Kagabu *, Takayuki Nagasawa, Chie Sato, Yasuko Fukagawa, Hanae Kawamura,
  Hidetoshi Tomabechi, Shuji Takemoto, Tadahiro Shoji
  and Tsukasa Baba
  Department of Obstetrics and Gynecology, Iwate Medical University School of Medicine, Morioka,
  Iwate 028-3695, Japan; tnagasaw@iwate-med.ac.jp (T.N.); c.kurokawa0825@gmail.com (C.S.);
  n5mykkhanae@yahoo.co.jp (H.K.); suga_yasuko@yahoo.co.jp (Y.F.); bechitomabehi@gmail.com (H.T.);
  tshyuuji@gmail.com (S.T.); tshoji@iwate-med.ac.jp (T.S.); babatsu@iwate-med.ac.jp (T.B.)
  * Correspondence: mkagabu@iwate-med.ac.jp; Tel.: +81-19-611-8007
  Received: 27 February 2020; Accepted: 25 March 2020; Published: 27 March 2020
  ����������
  �������
  Abstract: Immune checkpoint inhibitors (ICIs) have demonstrated marked clinical eﬀects worldwide,
  and “cancer immunotherapy” has been recognized as a feasible option for cance